However, the battle between the old and new paradigms of drug therapy continues to rage for different pharmacological treatments, and perhaps is most evident in the area of oral anticoagulants. From 1954–2009, warfarin was the only approved oral anticoagulant on the market with a long track ...
"Based on our study, digoxin should be avoided in patients with AFib, particularly if symptoms can be alleviated with other treatments," said Renato Lopes, MD, PhD, professor of medicine in the division of cardiology at Duke University Medical Center and lead author of the study. "We showed ...
has found a strong relationship between early-onset Afib and mutations that break TTN, a gene that helps maintain the structure of heart muscle. According to these new findings, roughly two percent of the nearly 2,800 early-onset Afib patients examined had ...
Our goals are to protect and restore your heart's health by offering comprehensive cardiovascular programs and treatments for all types of heart and vascular conditions. Our multidisciplinary team of experts uses the latest technology, conducts cutting-edge research, and participates in the latest clini...
companies. Headquartered in Ingelheim, Germany, the company operates globally with 146 affiliates and more than 47,000 employees. Since its founding in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel treatments forhumanand veterinary ...
Treatments with Vitamin K antagonists or novel oral anticoagulants (NOACs) can dramatically lower the risk of ischemic strokes in the presence of AFib. Non-adherence can expose the patients to an increased stroke risk. This is especially true for NOACs, due to their short half-life. Patients ...
"They have a lot of promise and are potentially very important," said Katherine Hamilton, a headache specialist at Penn Medicine. The drugs, which are injected under the skin, offer hope forpatientswho have not responded to other treatments, but Hamilton said that what is "potentially even mor...
One QALY equates to one year in perfect health and represents a single number that can be compared across different types of treatments [87]. Independent studies that assessed ICERs and QALY in previously untreated CLL were performed for the first-in-class BTKi ibrutinib, for acalabrutinib, ...